Boston Scientific gains approval for new version of heart stent
Boston Scientific Corp. said it gained US approval for a new version of its drug-coated heart stent, a product the company will manufacture itself rather than licensing from a competitor.
A study based on more than 1.5 million percutaneous coronary intervention procedures suggests that the use of drug-eluting stents varies widely among US physicians, and is only modestly correlated with the patient's risk of coronary artery restenosis, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.